Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 134900
Corporate User License Price USD 6000
Corporate User License Price INR 404700
Site License Price USD 4000
Site License Price INR 269800
Request a Quote

Report Title

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H1 2015

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H1 2015


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H1 2015

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H1 2015



Executive Summary

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H1 2015', provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Overview 6

Therapeutics Development 7

Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Overview 7

Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Comparative Analysis 8

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Therapeutics under Development by Companies 9

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Products under Development by Companies 12

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Companies Involved in Therapeutics Development 13

CTI BioPharma Corp. 13

Gilead Sciences, Inc. 14

Incyte Corporation 15

Italfarmaco S.p.A. 16

Nippon Shinyaku Co., Ltd. 17

Novartis AG 18

Promedior, Inc. 19

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

buparlisib hydrochloride-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

givinostat-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

INCB-39110-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

LCL-161-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

NS-018-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

pacritinib-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

PRM-151-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

simtuzumab-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Recent Pipeline Updates 46

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Dormant Projects 57

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Discontinued Products 58

Appendix 59

Methodology 59

Coverage 59

Secondary Research 59

Primary Research 59

Expert Panel Validation 59

Contact Us 59

Disclaimer 60

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Tables

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2015 7

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by CTI BioPharma Corp., H1 2015 13

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Gilead Sciences, Inc., H1 2015 14

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Incyte Corporation, H1 2015 15

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Italfarmaco S.p.A., H1 2015 16

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 17

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Novartis AG, H1 2015 18

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline by Promedior, Inc., H1 2015 19

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Stage and Target, H1 2015 22

Number of Products by Stage and Mechanism of Action, H1 2015 24

Number of Products by Stage and Route of Administration, H1 2015 26

Number of Products by Stage and Molecule Type, H1 2015 28

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics-Recent Pipeline Updates, H1 2015 46

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Dormant Projects, H1 2015 57

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Discontinued Products, H1 2015 58

List of Figures

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2015 7

Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 11

Assessment by Monotherapy Products, H1 2015 20

Number of Products by Top 10 Targets, H1 2015 21

Number of Products by Stage and Top 10 Targets, H1 2015 21

Number of Products by Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Top 10 Routes of Administration, H1 2015 25

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26

Number of Products by Top 10 Molecule Types, H1 2015 27

Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

CTI BioPharma Corp.

Gilead Sciences, Inc.

Incyte Corporation

Italfarmaco S.p.A.

Nippon Shinyaku Co., Ltd.

Novartis AG

Promedior, Inc.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutic Products under Development, Key Players in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics, Post-Polycythemia Vera Myelofibrosis (PPV-MF) Pipeline Overview, Post-Polycythemia Vera Myelofibrosis (PPV-MF) Pipeline, Post-Polycythemia Vera Myelofibrosis (PPV-MF) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand